Publicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (10)

2024

  1. Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2

    International Journal of Molecular Sciences, Vol. 25, Núm. 4

2023

  1. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned

    Journal of Hematology and Oncology, Vol. 16, Núm. 1

  2. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2

    Viruses, Vol. 15, Núm. 7

  3. Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal–Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities

    Cancers, Vol. 15, Núm. 12

2022

  1. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

2020

  1. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

    Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 1976-1991

2016

  1. BRCA2 gene mutations and coagulation-associated biomarkers

    Thrombosis and Haemostasis, Vol. 115, Núm. 2, pp. 415-423

2015

  1. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273

2014

  1. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain

    Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 273-279

2012

  1. Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis

    Neuro-Oncology, Vol. 14, Núm. 1, pp. 43-52